Usual doses of tigecycline — Competitive Intelligence Brief

Usual doses of tigecycline (Usual doses of tigecycline) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Infectious Disease.

marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit Infectious Disease Small molecule

Target snapshot

Usual doses of tigecycline (Usual doses of tigecycline) — Air Force Specialized Hospital, Cairo, Egypt. Tigecycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide elongation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Usual doses of tigecycline TARGET	Usual doses of tigecycline	Air Force Specialized Hospital, Cairo, Egypt	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Tetracyclin ointment	Tetracyclin ointment	University of Oslo	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Doxycycline post-exposure prophylaxis	Doxycycline post-exposure prophylaxis	University of Washington	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Cefazolin + Gentamicin	Cefazolin + Gentamicin	Mercy Health Ohio	marketed	Beta-lactam antibiotic + aminoglycoside antibiotic combination	Bacterial penicillin-binding proteins (cefazolin); bacterial 30S ribosomal subunit (gentamicin)
Doxycycline pre-operatively	Doxycycline pre-operatively	University of Pittsburgh	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Neomycin Oral Product	Neomycin Oral Product	South Australian Health and Medical Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Tigecycline antimicrobial-lock solution	Tigecycline antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic class)

1. OraPharma · 2 drugs in this class
2. Vyne Therapeutics Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
5. Darier · 1 drug in this class
6. Edward Lain, MD · 1 drug in this class
7. Generic (originally Pfizer) · 1 drug in this class
8. Galderma R&D · 1 drug in this class
9. Johns Hopkins University · 1 drug in this class
10. Chinese University of Hong Kong · 1 drug in this class